TLDR The letter is skeptical about the effectiveness of anti-androgen therapy for COVID-19 and calls for strong evidence from clinical trials.
The letter to the editor expresses skepticism regarding the claims that anti-androgen therapy, specifically 5-alpha-reductase inhibitors like finasteride and dutasteride, could reduce the severity of COVID-19 symptoms in males with androgenetic alopecia (AGA). The authors highlight a case of a 40-year-old man with AGA on finasteride who experienced severe COVID-19 symptoms, contradicting the hypothesis that anti-androgen therapy could be protective. They acknowledge ongoing studies on anti-androgen therapy for COVID-19 but call for extraordinary evidence to support such extraordinary claims. The letter also criticizes the rapid publication and self-citation practices of some authors in the field, suggesting a lack of robust evidence and a propensity for publicity. The authors urge for results from randomized, controlled clinical trials to validate any potential therapeutic benefits of anti-androgen treatment for COVID-19.
3 citations,
November 2020 in “Journal of The American Academy of Dermatology” The document suggests that more research is needed to confirm if baldness can indicate a higher risk of severe COVID-19 in men.
36 citations,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
4 citations,
August 2020 in “Journal of The American Academy of Dermatology” Hair loss link to COVID-19 severity likely due to other factors.
6 citations,
July 2020 in “Journal of The American Academy of Dermatology” Hair loss link to severe COVID-19 unclear.
32 citations,
July 2020 in “Journal of The American Academy of Dermatology” AGA linked to worse COVID-19 outcomes in men.
119 citations,
May 2020 in “Journal of The American Academy of Dermatology” Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.
134 citations,
April 2020 in “Journal of Cosmetic Dermatology” Male pattern hair loss could hint at androgens affecting COVID-19 severity.
47 citations,
April 2020 in “Dermatologic Therapy” Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.
3 citations,
March 2021 in “Journal of the European Academy of Dermatology and Venereology” The letter is skeptical about the effectiveness of anti-androgen therapy for COVID-19 and calls for strong evidence from clinical trials.
